课题基金 / 基金详情

The Efficacy of CBT-I in Alcoholics & Its Effects on Remission & Relapse

The Efficacy of CBT-I in Alcoholics & Its Effects on Remission & Relapse
CBT-I 对酗酒者的功效
批准号:
9240571
负责人:
Subhajit Chakravorty
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-01-01 至 2018-12-31
关键词:
AbateAbstinenceAddressAftercareAge of OnsetAlcohol dependenceAlcoholismAlcoholsAnxietyBackBeck depression inventoryBiological MarkersClinicalCognitive TherapyCohort StudiesComorbidityDataDisease remissionDrowsinessElectroencephalographyEquipment and supply inventoriesEvaluationExhibitsFamilyFamily history ofFatigueGeneral PopulationGeneralized Anxiety DisorderGeneticGoalsHealthHeavy DrinkingHourHygieneImpairmentIncidenceIndividualInterventionInvestigationLaboratoriesMaintenanceMeasuresMental disordersMilitary PersonnelModalityMoodsNeurobiologyOutcomeOutcome MeasureParticipantPathologicPatientsPerformance at workPharmaceutical PreparationsPharmacotherapyPhenotypePlacebosPopulationPrevalencePrimary Health CareProtocols documentationPsychophysiological InsomniaQuestionnairesRandomizedRecording of previous eventsRecoveryRecurrenceRegimenRelapseReplacement TherapyResearchRiskRisk FactorsSamplingSeveritiesSeverity of illnessSleepSleeplessnessStimulusTestingTimeTimeLineTrainingTrazodoneTreatment outcomeVeteransWithdrawalalcohol cravingalcohol misusealcoholism therapyanxiety symptomsawakebinge drinkingclinical effectclinically significantcravingdaily functioningdepressive symptomsdesensitizationdesigndiariesdrinkingeffective therapyexperiencefallsfollow-upgabapentinhealth related quality of lifeimprovedindexingmalemodifiable riskpost interventionprimary outcomeproblem drinkerpublic health relevancerecidivismrelapse risksecondary analysissobrietytargeted treatmenttraittreatment adherencetreatment effecttreatment responsetrend

项目摘要

项目成果

Subhajit Chakravorty的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):
英文摘要
DESCRIPTION (provided by applicant): Alcoholism and insomnia are highly prevalent in Veterans. Alcoholism is estimated to occur in about 6.4% of Veterans. More recent estimates of alcohol misuse range from 11.8% in OIF Veterans to 21.8% in OEF/OIF male Veterans. Insomnia is estimated to occur in about 28% of active duty military personnel (from the Millennium Cohort Study), and up to 77% of Veterans seen in a VHA primary care experience clinically significant levels of insomnia. Insomnia is also highly prevalent in patients recovering from alcoholism with as many as 70% of such patients complaining of sleep initiation and/or maintenance problems. These prevalence rates are 2-7 times higher than that of the general population. The direct consequences of insomnia include sleepiness, fatigue, irritability, diminished work performance and impaired interpersonal functioning. The long- term sequelae of insomnia include risk for new-onset and recurrent psychiatric illness, and in the context of alcoholism, greater intensity of alcoholism and increased risk for relapse in abstinent alcoholics. At present, there are nine studies which evaluate whether insomnia represents a modifiable risk factor for relapse of alcoholism (2 investigating trazodone, 3 investigating gabapentin, 1 investigating ramelteon, and 3 investigating a modified form of cognitive-behavioral therapy for insomnia [CBT-I]). The results from these studies are variable. The CBT-I investigations show the most promise in terms of improved sleep, but there is no clear evidence that improved sleep has protective value against pathological drinking. Accordingly, CBT-I (n=30) will be evaluated and compared to the Quasi-Desensitization Therapy (QDT) (n=30) in a sample of veterans who have been sober for at least one month (but less than one year). The study cohort will be further stratified into those who do (n=30) and do not (n=30) have a first-degree family history of alcoholism. Familial alcoholism is taken into account, as this may represent a unique factor that contributes to insomnia severity and/or treatment outcome. All subjects will complete a 2-week baseline recording period followed by weekly CBT-I/QDT sessions for 8-weeks. CBT-I will be conducted according to a standard protocol. Weekly 1-hour sessions (individual format) will be used to deliver the four components of CBT-I (Sleep Restriction, Stimulus Control, Sleep Hygiene, and Cognitive therapy [sleep-related de-catastrophization]). Treatment will be followed up with two evaluations at 3 and 6 months post-intervention. All subjects will complete the Insomnia Severity Index, daily sleep diaries, and the alcohol-related measures for a 2-week baseline, for the intervention period, and for two follow-up intervals after treatment completion at 3 and 6 months. The primary outcome measures are insomnia severity (as assessed with the ISI) and percentage days abstinent (as assessed using the Timeline Follow Back measure). In addition, health and mood will be tracked using the Short Form-12 (SF-12) item scale, the BDI-II, PHQ9, STAI, and the GAD7. The combination of these measures serve to test the hypotheses that standard CBT-I can be applied successfully in patients recovering from alcoholism and that successful treatment of insomnia will be associated with better clinical outcomes in relation to alcoholism. Finally, family history data will be assessed on an exploratory basis to assess differences in baseline insomnia and objective sleep, as well as outcomes for the insomnia, alcoholism, treatment adherence, and/or treatment outcome. Objective sleep will be preliminarily assessed with in-laboratory polysomnograms of seven subjects with and without familial alcoholism (n=16). It is hypothesized that CBT-I in abstinent alcoholics will lead to 1) significantly superio sleep-related outcomes as compared to QDT, 2) pre-to-post treatment effect sizes that are comparable to the meta-analytic norms, 3) a larger percentage of days abstinent with at least a trend toward fewer relapses, and 4) better overall health and mood. If these findings are achieved and replicated, it will suggest that insomnia treatment should be a standard component in the management of alcoholism and that CBT-I is an ideal management approach for this co-morbid insomnia.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cognitive Behavioral Therapy (CBT-I) Augmentation of Topiramate in promoting abstinence in alcohol use disorder (AUD).
  • 批准号:
    10013402
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2020
  • 负责人:
    Subhajit Chakravorty
  • 依托单位:
Cognitive Behavioral Therapy (CBT-I) Augmentation of Topiramate in promoting abstinence in alcohol use disorder (AUD).
  • 批准号:
    10578700
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2020
  • 负责人:
    Subhajit Chakravorty
  • 依托单位:
Cognitive Behavioral Therapy (CBT-I) Augmentation of Topiramate in promoting abstinence in alcohol use disorder (AUD).
  • 批准号:
    10394786
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2020
  • 负责人:
    Subhajit Chakravorty
  • 依托单位:
The Efficacy of CBT-I in Alcoholics & Its Effects on Remission & Relapse
  • 批准号:
    8634474
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2014
  • 负责人:
    Subhajit Chakravorty
  • 依托单位:
海外基金